Literature DB >> 11015306

Inverse agonism and neutral antagonism at a constitutively active alpha-1a adrenoceptor.

J Zhu1, T Taniguchi, R Takauji, F Suzuki, T Tanaka, I Muramatsu.   

Abstract

We have studied the antagonist action of prazosin and KMD-3213 in a constitutively active mutant of the human alpha-1a adrenoceptor in which Ala(271) was substituted to Thr and was expressed in CHO cells. Inverse agonism was characterized by up-regulation of receptor density, a decrease in basal GTPgammaS binding, and a reduction in basal inositol-1,4,5-trisphosphate (IP(3)) level. According to the above criteria, prazosin acted as an inverse agonist, whilst KMD-3213 behaved as a neutral antagonist. Compared with the wild-type receptor, mutant receptor exhibited single affinity sites for [(3)H]-prazosin, [(3)H]-KMD and the non-radioactive ligands tested, and displayed significantly higher affinities for several agonists but not for the two antagonists. Administration of KMD-3213 to prazosin-treated CHO cells expressing the mutant receptor reversed the inverse agonism of prazosin resulting in rapid increases in cellular IP(3), in intracellular [Ca(2+)] and in the rate of extracellular acidification. These results indicated that a neutral antagonist can reverse the action of an inverse agonist at the receptor site. The distinct properties of inverse agonist and neutral antagonist in affecting receptor function may be important for the clinical use of such antagonists.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11015306      PMCID: PMC1572343          DOI: 10.1038/sj.bjp.0703584

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  26 in total

1.  Inverse agonism of histamine H2 antagonist accounts for upregulation of spontaneously active histamine H2 receptors.

Authors:  M J Smit; R Leurs; A E Alewijnse; J Blauw; G P Van Nieuw Amerongen; Y Van De Vrede; E Roovers; H Timmerman
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

Review 2.  alpha 1-adrenergic receptor subtypes. Molecular structure, function, and signaling.

Authors:  R M Graham; D M Perez; J Hwa; M T Piascik
Journal:  Circ Res       Date:  1996-05       Impact factor: 17.367

3.  Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas.

Authors:  J Parma; L Duprez; J Van Sande; P Cochaux; C Gervy; J Mockel; J Dumont; G Vassart
Journal:  Nature       Date:  1993-10-14       Impact factor: 49.962

Review 4.  Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins.

Authors:  R J Lefkowitz; S Cotecchia; P Samama; T Costa
Journal:  Trends Pharmacol Sci       Date:  1993-08       Impact factor: 14.819

5.  Constitutively active 5-hydroxytryptamine2C receptors reveal novel inverse agonist activity of receptor ligands.

Authors:  E L Barker; R S Westphal; D Schmidt; E Sanders-Bush
Journal:  J Biol Chem       Date:  1994-04-22       Impact factor: 5.157

6.  Selectivity of agonists for cloned alpha 1-adrenergic receptor subtypes.

Authors:  K P Minneman; T L Theroux; S Hollinger; C Han; T A Esbenshade
Journal:  Mol Pharmacol       Date:  1994-11       Impact factor: 4.436

7.  The unique nature of the serine interactions for alpha 1-adrenergic receptor agonist binding and activation.

Authors:  J Hwa; D M Perez
Journal:  J Biol Chem       Date:  1996-03-15       Impact factor: 5.157

8.  Myocardial expression of a constitutively active alpha 1B-adrenergic receptor in transgenic mice induces cardiac hypertrophy.

Authors:  C A Milano; P C Dolber; H A Rockman; R A Bond; M E Venable; L F Allen; R J Lefkowitz
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-11       Impact factor: 11.205

9.  Physiological effects of inverse agonists in transgenic mice with myocardial overexpression of the beta 2-adrenoceptor.

Authors:  R A Bond; P Leff; T D Johnson; C A Milano; H A Rockman; T R McMinn; S Apparsundaram; M F Hyek; T P Kenakin; L F Allen
Journal:  Nature       Date:  1995-03-16       Impact factor: 49.962

10.  Inverse agonist activity of beta-adrenergic antagonists.

Authors:  P Chidiac; T E Hebert; M Valiquette; M Dennis; M Bouvier
Journal:  Mol Pharmacol       Date:  1994-03       Impact factor: 4.436

View more
  11 in total

1.  Detection of receptor ligands by monitoring selective stabilization of a Renilla luciferase-tagged, constitutively active mutant, G-protein-coupled receptor.

Authors:  D Ramsay; N Bevan; S Rees; G Milligan
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

2.  Probing the correlation between ligand efficacy and conformational diversity at the α1A-adrenoreceptor reveals allosteric coupling of its microswitches.

Authors:  Feng-Jie Wu; Lisa M Williams; Alaa Abdul-Ridha; Avanka Gunatilaka; Tasneem M Vaid; Martina Kocan; Alice R Whitehead; Michael D W Griffin; Ross A D Bathgate; Daniel J Scott; Paul R Gooley
Journal:  J Biol Chem       Date:  2020-04-17       Impact factor: 5.157

3.  Alpha-1 adrenoceptor up-regulation induced by prazosin but not KMD-3213 or reserpine in rats.

Authors:  Li Zhang; Takanobu Taniguchi; Takashi Tanaka; Kazumasa Shinozuka; Masaru Kunitomo; Masahiko Nishiyama; Koji Kamata; Ikunobu Muramatsu
Journal:  Br J Pharmacol       Date:  2002-04       Impact factor: 8.739

Review 4.  Feedback regulation of G protein-coupled receptor signaling by GRKs and arrestins.

Authors:  Joseph B Black; Richard T Premont; Yehia Daaka
Journal:  Semin Cell Dev Biol       Date:  2016-01-07       Impact factor: 7.727

5.  Novel role of mechanosensitive AT1B receptors in myogenic vasoconstriction.

Authors:  Stephanie Blodow; Holger Schneider; Ursula Storch; Richard Wizemann; Anna-Lena Forst; Thomas Gudermann; Michael Mederos y Schnitzler
Journal:  Pflugers Arch       Date:  2013-10-08       Impact factor: 3.657

6.  alpha(1A)- and alpha(1B)-adrenergic receptors differentially modulate antidepressant-like behavior in the mouse.

Authors:  Van A Doze; Evelyn M Handel; Kelly A Jensen; Belle Darsie; Elizabeth J Luger; James R Haselton; Jeffery N Talbot; Boyd R Rorabaugh
Journal:  Brain Res       Date:  2009-06-18       Impact factor: 3.252

7.  BIGL: Biochemically Intuitive Generalized Loewe null model for prediction of the expected combined effect compatible with partial agonism and antagonism.

Authors:  Koen Van der Borght; Annelies Tourny; Rytis Bagdziunas; Olivier Thas; Maxim Nazarov; Heather Turner; Bie Verbist; Hugo Ceulemans
Journal:  Sci Rep       Date:  2017-12-20       Impact factor: 4.379

8.  Evidence for altered brain reactivity to norepinephrine in Veterans with a history of traumatic stress.

Authors:  Rebecca C Hendrickson; Murray A Raskind; Steven P Millard; Carl Sikkema; Garth E Terry; Kathleen F Pagulayan; Ge Li; Elaine R Peskind
Journal:  Neurobiol Stress       Date:  2018-03-15

9.  A Systematic Review of Inverse Agonism at Adrenoceptor Subtypes.

Authors:  Martin C Michel; Martina B Michel-Reher; Peter Hein
Journal:  Cells       Date:  2020-08-19       Impact factor: 6.600

Review 10.  Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism.

Authors:  Andrea de Bartolomeis; Carmine Tomasetti; Felice Iasevoli
Journal:  CNS Drugs       Date:  2015-09       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.